Companies have scant financial incentive to develop new antibiotics. Will the NIH continue to support relevant research?

In July 2025, Marengo Therapeutics Inc. organized a phase 1/2 study to assess the safety/tolerability and preliminary ...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.

DelveInsight's,“ Thyroid Cancer Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 51+ ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a ...